Corrigendum

To cite this article: (2009) Corrigendum, Expert Opinion on Therapeutic Targets, 13:2, 265-265, DOI: 10.1517/14728220802704467

To link to this article: https://doi.org/10.1517/14728220802704467

Published online: 13 Jan 2009.

Submit your article to this journal

Article views: 81

View related articles
In the article “Current and emerging paradigms in the therapeutic management of atherosclerosis”, published in the December 2008 issue of Expert Opinion on Therapeutic Targets (Expert Opin Ther Targets (2008) 12(12):1523-46), two statements have been identified that have been found to be inaccurate.

In the abstract,

‘With the recent failure of torcetrapib, cordaptive and succinobucol, belonging to different target classes of drugs, in clinical trials, drug discovery and development efforts towards the treatment of atherosclerosis have received a big jolt and have been slowed down to a certain extent’.

should have been modified to read:

‘With the recent failure of torcetrapib and succinobucol, drug discovery and development efforts towards the treatment of atherosclerosis have received a big jolt and have been slowed down to a certain extent.’

In addition, on page 1530, the sentence ‘Cordaptive had no effect on niacin’s lipid-modifying effects and also did not affect the pharmacokinetics of niacin’ is incorrect and should not have been published.

The publishers would like to apologise for these errors and for any inconvenience caused.